Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying the right ones involves navigating significant risks and volatility [1] Group 1: Company Overview - Tactile Systems Technology (TCMD) is currently highlighted as a recommended growth stock by the Zacks Growth Style Score system, which evaluates a company's genuine growth potential [2] - The company holds a favorable Growth Score and a top Zacks Rank, indicating strong investment potential [2] Group 2: Earnings Growth - Tactile Systems Technology has a historical EPS growth rate of 17.9%, but the projected EPS growth for this year is significantly higher at 38.6%, surpassing the industry average of 10.4% [4] Group 3: Asset Utilization - The company's asset utilization ratio (sales-to-total-assets ratio) is 1.21, indicating that it generates $1.21 in sales for every dollar in assets, which is notably higher than the industry average of 0.6 [6] - Tactile Systems Technology's sales are expected to grow by 9.1% this year, compared to the industry average of 8.7% [6] Group 4: Earnings Estimate Revisions - The current-year earnings estimates for Tactile Systems Technology have been revised upward, with the Zacks Consensus Estimate increasing by 17.6% over the past month, reflecting a positive trend in earnings estimate revisions [7] Group 5: Investment Positioning - Tactile Systems Technology has achieved a Zacks Rank of 2 (Buy) and a Growth Score of B, positioning it favorably for potential outperformance in the growth stock category [9]

Drugmakers Novo Nordisk and Eli Lilly are battling it out in the GLP-1 weight loss market. The pill version of Novo Nordisk's Ozempic has reignited competition between theses two fierce rivals. Meanwhile, another major presence in the medical world -- device maker Intuitive Surgical (NASDAQ: ISRG) -- continues to chug along. And it looks set to do so regardless of which drug company wins the GLP-1 race. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best sto ...

Core Insights - GE HealthCare Technologies Inc. (GEHC) has received FDA 510(k) clearance for three new MRI innovations, which include SIGNA Sprint with Freelium, SIGNA Bolt, and SIGNA One, aimed at addressing challenges in the radiology market [1][2][4] Company Developments - The new SIGNA MRI systems are designed to enhance imaging access and efficiency, with a focus on reducing power consumption and helium reliance while improving image quality through AI tools [8][9][10] - SIGNA Sprint with Freelium is a 1.5T MRI platform that operates with less than 1% helium reliance, ensuring power efficiency and high imaging performance [9] - SIGNA Bolt, a next-generation 3T MRI system, features a deep-learning architecture that improves efficiency and sustainability, with 30% lower power consumption compared to previous models [10] - SIGNA One serves as the digital backbone of the MRI ecosystem, integrating AI-driven workflows to enhance efficiency and user experience [11] Market Position and Performance - Following the announcement of the new MRI systems, GEHC's shares increased by 0.1%, with a 12.3% rise over the past six months, contrasting with a 12.9% decline in the industry [3] - GEHC currently holds a market capitalization of $37.80 billion [6] Industry Trends - The magnetic resonance imaging market is projected to reach $8.8 billion by 2026, with a compound annual growth rate (CAGR) of 3.9% through 2035 [12] - Factors driving market growth include rising demand for advanced diagnostic imaging in neurology, oncology, and cardiology, as well as increased healthcare infrastructure investment [13] Additional Initiatives - GE HealthCare has expanded its contract with the Biomedical Advanced Research and Development Authority (BARDA) by $35 million to accelerate the development of AI-enabled ultrasound and imaging solutions [14] - The company has introduced ReadyFix, a remote fleet management platform aimed at improving medical device uptime and operational efficiency [15]

Core Insights - Integer Holdings Corporation (ITGR) reported adjusted earnings per share (EPS) of $1.76 for Q4 2025, a 23.1% increase year over year, exceeding the Zacks Consensus Estimate by 3.5% [1] - The company achieved revenues of $472.1 million in Q4 2025, reflecting a 5% year-over-year growth and surpassing the Zacks Consensus Estimate by 2% [2] - For the full year 2025, ITGR's revenues reached $1.85 billion, an 8% increase compared to 2024, with full-year EPS of $6.4, up 21% year over year [2] Revenue Breakdown - The Cardio and Vascular (C&V) segment generated revenues of $284.2 million in Q4 2025, an 11.3% increase year over year, driven by new product ramps and strong customer demand [5] - The Cardiac Rhythm Management & Neuromodulation (CRM&N) segment reported revenues of $167.3 million, down 1.9% year over year, due to a decline in Neuromodulation demand [6] - Revenues from the Other Markets segment totaled $20.5 million, down 13.2% year over year, attributed to the planned exit from the Portable Medical market [7] Margin and Expense Analysis - Gross profit for Q4 2025 was $124.8 million, a 6.8% increase year over year, with a gross margin of 26.4%, expanding by 50 basis points [8] - Selling, general and administrative expenses rose to $57.2 million, up 20.5% year over year, while total operating expenses increased by 15.2% to $68.8 million [10] - Adjusted operating profit was $83.3 million, reflecting a 9.6% increase from the prior year, with an adjusted operating margin of 17.6% [10] Financial Position - At the end of Q4 2025, ITGR had cash and cash equivalents of $17.2 million, down from $58.9 million at the end of Q3 2025, with total debt remaining flat at $1.19 billion [11] - Cumulative net cash flow from operating activities was $196.1 million, compared to $205.2 million a year ago [11] 2026 Guidance - For 2026, ITGR expects revenues between $1.826 billion and $1.876 billion, indicating a potential change of -1% to 1% from 2025 [12] - The company anticipates full-year adjusted EPS in the range of $6.29 to $6.78, reflecting a change of -2% to 6% from the previous year [12] Market Performance - Despite strong Q4 results, ITGR shares fell approximately 4% as investors focused on the 2026 guidance, which indicates slower adoption of new products [14] - Over the last six months, ITGR shares have declined by 22.7%, contrasting with a 4.9% decline in the industry and a 9.6% increase in the S&P 500 Index [15]

A month has gone by since the last earnings report for Johnson & Johnson (JNJ) . Shares have added about 13% in that time frame, outperforming the S&P 500.But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Johnson & Johnson due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Johnson & Johnson before we dive into how investors and analysts ...

Core Viewpoint - Outset Medical, Inc. (NASDAQ:OM) has shown resilience in its stock performance despite a decline in price targets from analysts following its fourth-quarter results, which largely met expectations [2][8]. Financial Performance - The fourth-quarter revenue for Outset Medical was reported at $28.90 million, reflecting a 2% year-over-year decrease [4]. - Total revenue for the year 2025 was $119.50 million, marking a 5% increase compared to the previous year [4]. - The full-year margin improved to 39.10%, while the quarterly gross margin increased by 600 basis points to 42.40% [4]. Analyst Insights - Analysts from TD Cowen and BTIG have adjusted their price targets to $12 and $15 respectively, while maintaining 'Buy' ratings, indicating continued confidence in the stock [2]. - BTIG highlighted that a stable sales force, an upcoming product launch, a wide deal pipeline, robust recurring revenue, and improving margins are expected to help restore the company's credibility [3]. Future Projections - Management has projected 2026 revenue to be between $125 million and $130 million, with a non-GAAP gross margin anticipated in the low-to-mid-40% range [5]. - The company plans to launch its next-generation Tablo platform in the second quarter of 2026 [5]. Company Overview - Outset Medical, founded in 2003 in San Jose, specializes in dialysis solutions through its Tablo Hemodialysis System, which facilitates both acute and home treatment [6].

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) reported better-than-expected fourth-quarter financial results on Thursday.Tandem Diabetes Care reported quarterly losses of 1 cent per share which beat the analyst consensus estimate of losses of 8 cents per share. The company reported quarterly sales of $290.400 million which beat the analyst consensus estimate of $277.029 million.Tandem Diabetes Care said it sees FY2026 sales of $1.065 billion to $1.085 billion, versus market estimates of $1.103 billion.“2025 was ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) reported better-than-expected fourth-quarter financial results on Thursday.Tandem Diabetes Care reported quarterly losses of 1 cent per share which beat the analyst consensus estimate of losses of 8 cents per share. The company reported quarterly sales of $290.400 million which beat the analyst consensus estimate of $277.029 million.Tandem Diabetes Care said it sees FY2026 sales of $1.065 billion to $1.085 billion, versus market estimates of $1.103 billion.“2025 was ...

Core Insights - Boston Scientific (BSX) and Abbott (ABT) are prominent players in the U.S. MedTech sector, attracting significant investor interest due to their diversified business models and innovative product offerings [1][2] Boston Scientific Overview - Boston Scientific's operational sales grew by 14% year over year in Q4 2025, exceeding the Zacks Consensus Estimate by 2.6% [3] - The company anticipates a return to market growth in Urology in 2026, driven by new product launches and the sacral neuromodulation franchise [3] - The acquisition of Valencia is expected to enhance Boston Scientific's pelvic health portfolio [3] - Neuromodulation performance is bolstered by strong brain and pain franchises, with the Nalu acquisition expanding into peripheral nerve pain [4] - The Interventional Cardiology Therapies segment is benefiting from the AGENT Drug-Coated Balloon, with plans to expand indications for SEISMIQ IVL [5] - WATCHMAN sales increased by 29% year over year in Q4, supported by strong adoption rates [6] - Boston Scientific's adjusted gross and operating margins expanded by 30 and 100 basis points, respectively, despite challenges from product discontinuations [7] Abbott Overview - Abbott's Q4 2025 sales rose by 4.4% year over year but fell short of the Zacks Consensus Estimate by 2.8% [8] - The company is transitioning to a volume-driven business model in Nutrition, with plans to introduce at least eight new products in the next 12 months [8] - Abbott's Established Pharmaceuticals business is benefiting from high-demand therapeutic areas and advancing its biosimilar strategy in emerging markets [9] - The FreeStyle Libre CGM system achieved over $7.5 billion in sales in 2025, marking three consecutive years of over $1 billion in annual revenues [10] - Abbott's Medical Devices segment achieved several milestones, including regulatory approvals and national coverage for key products [11] - The acquisition of Exact Sciences is a strategic move to expand into cancer diagnostics [12] Financial Estimates and Performance - The consensus estimate for Boston Scientific's 2025 EPS is $3.46, reflecting a 13.1% year-over-year increase [13] - Abbott's consensus estimate for 2026 EPS is $5.68, indicating a 10.3% improvement over 2025 [15] - Over the past six months, Boston Scientific shares have declined by 27.9%, while Abbott shares have decreased by 15% [16] - Boston Scientific is trading at a forward five-year Price/Sales (P/S) ratio of 4.96, while Abbott's is at 4.05 [16] Investment Considerations - Both companies are taking strategic actions to enhance long-term growth prospects, with Boston Scientific showing strong performance in key business units [18] - Abbott's recent performance reflects broad-based growth, particularly in Electrophysiology and CGM [20] - Analysts are optimistic about both companies, with rising earnings estimates, but Abbott appears more attractive in terms of valuation and recent performance [20]

Core Viewpoint - Sonova's full year revenue is expected to be at the lower end of its 2025/2026 growth forecast range of 5% to 9% according to CEO Eric Bernard [1] Company Summary - Sonova is a hearing-aid manufacturer [1] - The company is projecting a revenue growth forecast for the fiscal year 2025/2026 between 5% and 9% [1]